Trexquant Investment LP lessened its position in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 36.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 172,551 shares of the company's stock after selling 99,119 shares during the quarter. Trexquant Investment LP owned about 0.74% of UroGen Pharma worth $1,838,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. Rhumbline Advisers lifted its stake in shares of UroGen Pharma by 2.8% in the 4th quarter. Rhumbline Advisers now owns 51,270 shares of the company's stock valued at $546,000 after purchasing an additional 1,402 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in UroGen Pharma by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company's stock worth $996,000 after buying an additional 3,024 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in shares of UroGen Pharma in the 4th quarter valued at approximately $59,000. BNP Paribas Financial Markets boosted its position in shares of UroGen Pharma by 221.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company's stock worth $109,000 after purchasing an additional 5,890 shares during the period. Finally, Tidal Investments LLC boosted its position in shares of UroGen Pharma by 19.1% during the third quarter. Tidal Investments LLC now owns 37,595 shares of the company's stock worth $477,000 after buying an additional 6,030 shares during the period. 91.29% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity at UroGen Pharma
In other news, insider Mark Schoenberg sold 4,551 shares of the company's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the sale, the insider now directly owns 145,666 shares of the company's stock, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Jason Drew Smith sold 7,379 shares of the firm's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the transaction, the general counsel now directly owns 26,468 shares in the company, valued at approximately $294,853.52. This represents a 21.80 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.10% of the company's stock.
Analyst Ratings Changes
Several analysts have recently issued reports on URGN shares. D. Boral Capital reissued a "buy" rating and set a $25.00 price target on shares of UroGen Pharma in a research report on Monday, March 10th. LADENBURG THALM/SH SH assumed coverage on UroGen Pharma in a research report on Wednesday, February 19th. They set a "buy" rating and a $31.00 price objective on the stock. Finally, HC Wainwright lowered their target price on UroGen Pharma from $64.00 to $55.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $38.20.
Read Our Latest Stock Report on UroGen Pharma
UroGen Pharma Stock Up 3.1 %
NASDAQ URGN traded up $0.32 during trading on Monday, reaching $10.44. 62,420 shares of the company's stock were exchanged, compared to its average volume of 508,835. The company has a 50 day moving average price of $10.56 and a two-hundred day moving average price of $11.25. The stock has a market cap of $481.13 million, a P/E ratio of -3.31 and a beta of 0.80. UroGen Pharma Ltd. has a 1 year low of $8.94 and a 1 year high of $20.70. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00.
UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its earnings results on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The company had revenue of $24.57 million during the quarter, compared to analysts' expectations of $25.25 million. On average, equities research analysts anticipate that UroGen Pharma Ltd. will post -3.12 EPS for the current fiscal year.
About UroGen Pharma
(
Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Featured Stories
Before you consider UroGen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.
While UroGen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
